Research
Hormonal
Dietary intervention (weight loss maintenance) increases circulating Heme-oxygenase-1 (HO-1) levels, with a non-significant trend toward greater increases on Low Glycemic Index diets.
Weight loss maintenance increases HO-1, an enzyme that may help reduce oxidative stress. While the type of diet matters less for HO-1, Low Glycemic Index diets showed a trend toward higher increases. This is a minor benefit of weight loss.
ModerateSupportsMEDIUM confidence
Heme-oxygenase-1 (HO-1) increased (P = 0.003), without differential effect by macronutrient composition (LF 0.40 ± 0.26, LGI 0.98 ± 0.63, VLC 0.49 ± 0.29 ng/mL, P = 0.07).
Why this rating
Statistically significant increase, but sample size for HO-1 was smaller (N=16) and macronutrient differences were not significant.
Source
Hepatic, adipocyte, enteric and pancreatic hormones: response to dietary macronutrient composition and relationship with metabolism
Bridget M. Hron et al. · Nutrition & Metabolism · 2017
DOI 10.1186/s12986-017-0198-y
crossover · n=21Cited 15×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dietary interventions that induce weight loss decrease circulating FGF-21 levels, with the magnitude of decrease being inversely proportional to carbohydrate content (very low carbohydrate diets causing the greatest reduction).Good
- Decreases in FGF-21 levels during weight loss maintenance are associated with improvements in hepatic insulin sensitivity, suggesting a resolution of FGF-21 resistance.Good
- Dietary intervention (weight loss maintenance) increases fasting ghrelin levels and decreases chemerin levels, independent of macronutrient composition.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →